CVS Group Q4 Earnings Call Highlights

CVS Group said full-year revenue topped GBP 710 million, up 5.9%, and expects adjusted EBITDA to be in line with consensus with margins broadly flat at about 20%. Net debt was about GBP 200 million, leaving leverage comfortably below the company’s two-times limit. Management highlighted Australia as a major growth driver, with six acquisitions completed this year and more deals in progress. CVS now operates 57 Australian practice sites and believes the business could eventually deliver GBP 105 million to GBP 135 million of EBITDA over time. The company reaffirmed its capital allocation priorities, including maintaining a strong balance sheet, funding growth investment, and returning cash to shareholders through dividends and a GBP 50 million buyback. CVS also said it expects about GBP 50 million a year for acquisitions and about GBP 30 million a year in total capital investment.

CVS Group said revenue for the financial year ended June 30 exceeded GBP 710 million, up 5.9% from the prior year, as the veterinary services provider used an investor presentation to reiterate its capital allocation policy and outline expected returns from acquisitions and capital investment. Chief Executive Richard Fairman said growth was generated across all three divisions, with like-for-like revenue growth of 2.1% for the full year. He said trading in the final quarter was affected by continued weakness in U.K. consumer confidence and “exceptionally hot spells of weather” in late May and late June, which led some customers to defer routine appointments or cancel scheduled procedures.

Fairman said CVS expects to report full-year adjusted EBITDA in line with market consensus, with adjusted EBITDA margin expected to be broadly flat at about 20%. Net debt at the end of June was approximately GBP 200 million, and leverage stood at 1.63 times, below the company’s stated maximum of two times.

Fairman said CVS operates in a veterinary market supported by long-term structural growth, citing the humanization of pets, a larger pet population since the COVID-19 pandemic, longer pet life expectancy and advances in clinical care. He said the company had “never experienced a full year of negative growth” and argued that veterinary care has shown resilience through economic cycles. CVS operates more than 475 practices in the U.K. and Australia. Veterinary practices currently account for about 89% of group revenue, with laboratories contributing 4.5% and the Animed Direct online retail business accounting for about 7%. The group employs around 9,000 people, including 2,500 veterinarians and 3,300 nurses.

Fairman also discussed the impact of the U.K. Competition and Markets Authority process, saying CVS now has “CMA certainty.” He said the company has displayed prices on all U.K. companion animal websites from late 2025 and has more than 80% of U.K. practices jointly branded. He added that the company has put through higher price changes this summer than in the prior three years, after previously taking a more cautious approach during the CMA process.

Chief Financial Officer Robin Alfonso said CVS’s capital allocation priorities remain unchanged. He said the company’s first priority is maintaining a healthy balance sheet, noting that CVS recently refinanced its bank debt and now has committed facilities through May 2030, with a one-year extension at the company’s discretion. Alfonso said CVS benefits from operating cash conversion above 70%, providing capacity for organic growth, acquisitions and shareholder returns. He said CVS expects to recommend a final dividend fo...